It takes two to tango: NAD(+) and sirtuins in aging/longevity control
View on PubMed → | DOI | Publisher
Plain-language summary
Published 2016 in NPJ Aging Mech Dis, this work by Imai SI and collaborators tackles a specific question within science-focused NMN/NAD+ research.
Key findings reported by the authors
- Review article in NPJ Aging Mech Dis (2016) summarising the state of NAD+/NMN/sirtuin science
- Useful synthesis for understanding mechanism and evidence quality
- Cited as reference for NAD+ booster therapeutic claims
What this means for Malaysian buyers
For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.